JAM-A functions as a female microglial tumor suppressor in glioblastoma.
glioblastoma
junctional adhesion molecule A
microglia
sex differences
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
26 11 2020
26 11 2020
Historique:
pubmed:
28
6
2020
medline:
17
3
2021
entrez:
28
6
2020
Statut:
ppublish
Résumé
Glioblastoma (GBM) is the most aggressive primary brain tumor and has a dismal prognosis. Previously, we identified that junctional adhesion molecule A (JAM-A), a cell adhesion molecule, is highly elevated in human GBM cancer stem cells and predicts poor patient prognosis. While JAM-A is also highly expressed in other cells in the tumor microenvironment, specifically microglia and macrophages, how JAM-A expression in these cells affects tumor growth has yet to be determined. The goal of this study was to understand the role of microenvironmental JAM-A in mediating GBM growth. Male and female wild-type (WT) and JAM-A-deficient mice were transplanted intracranially with the syngeneic glioma cell lines GL261 and SB28 and were assessed for differences in survival and microglial activation in tumors and in vitro. RNA-sequencing was performed to identify differentially regulated genes among all genotypes, and differences were validated in vitro and in vivo. We found that JAM-A-deficient female mice succumbed to GBM more quickly compared with WT females and JAM-A-deficient and male WT mice. Analysis of microglia in the tumors revealed that female JAM-A-deficient microglia were more activated, and RNA-sequencing identified elevated expression of Fizz1 and Ifi202b specifically in JAM-A-deficient female microglia. Our findings suggest that JAM-A functions to suppress pathogenic microglial activation in the female tumor microenvironment, highlighting an emerging role for sex differences in the GBM microenvironment and suggesting that sex differences extend beyond previously reported tumor cell-intrinsic differences.
Sections du résumé
BACKGROUND
Glioblastoma (GBM) is the most aggressive primary brain tumor and has a dismal prognosis. Previously, we identified that junctional adhesion molecule A (JAM-A), a cell adhesion molecule, is highly elevated in human GBM cancer stem cells and predicts poor patient prognosis. While JAM-A is also highly expressed in other cells in the tumor microenvironment, specifically microglia and macrophages, how JAM-A expression in these cells affects tumor growth has yet to be determined. The goal of this study was to understand the role of microenvironmental JAM-A in mediating GBM growth.
METHODS
Male and female wild-type (WT) and JAM-A-deficient mice were transplanted intracranially with the syngeneic glioma cell lines GL261 and SB28 and were assessed for differences in survival and microglial activation in tumors and in vitro. RNA-sequencing was performed to identify differentially regulated genes among all genotypes, and differences were validated in vitro and in vivo.
RESULTS
We found that JAM-A-deficient female mice succumbed to GBM more quickly compared with WT females and JAM-A-deficient and male WT mice. Analysis of microglia in the tumors revealed that female JAM-A-deficient microglia were more activated, and RNA-sequencing identified elevated expression of Fizz1 and Ifi202b specifically in JAM-A-deficient female microglia.
CONCLUSIONS
Our findings suggest that JAM-A functions to suppress pathogenic microglial activation in the female tumor microenvironment, highlighting an emerging role for sex differences in the GBM microenvironment and suggesting that sex differences extend beyond previously reported tumor cell-intrinsic differences.
Identifiants
pubmed: 32592484
pii: 5864028
doi: 10.1093/neuonc/noaa148
pmc: PMC7690368
doi:
Substances chimiques
Junctional Adhesion Molecule A
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1591-1601Subventions
Organisme : NCI NIH HHS
ID : R01 CA213843
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS083629
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA059366
Pays : United States
Organisme : NCI NIH HHS
ID : F32 CA243314
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007250
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS112526
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
PLoS One. 2012;7(2):e30763
pubmed: 22363486
Cell Rep. 2018 Sep 4;24(10):2773-2783.e6
pubmed: 30184509
Neuro Oncol. 2016 Oct 1;18(suppl_5):v1-v75
pubmed: 28475809
Nat Cell Biol. 2015 Feb;17(2):170-82
pubmed: 25580734
Glia. 2008 Dec;56(16):1799-808
pubmed: 18661554
Glia. 2011 Mar;59(3):472-85
pubmed: 21264953
Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2005-11
pubmed: 16809549
Neuro Oncol. 2019 Jan 1;21(1):71-82
pubmed: 30124908
PLoS One. 2011;6(10):e27040
pubmed: 22046441
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):2165-71
pubmed: 12958043
J Pathol. 2008 Sep;216(1):15-24
pubmed: 18553315
Neuro Oncol. 2016 May;18(5):656-66
pubmed: 26374689
JCI Insight. 2017 Jun 2;2(11):
pubmed: 28570266
J Periodontal Implant Sci. 2018 Oct 24;48(5):284-294
pubmed: 30405936
J Neurosci. 2014 Sep 3;34(36):11929-47
pubmed: 25186741
Cancer Res. 2008 Dec 15;68(24):10358-66
pubmed: 19074905
Cell Stem Cell. 2010 May 7;6(5):421-32
pubmed: 20452317
J Exp Med. 2017 Jan;214(1):17-25
pubmed: 27923908
J Steroid Biochem Mol Biol. 2016 Jun;160:127-33
pubmed: 26435451
Int J Mol Sci. 2018 Mar 27;19(4):
pubmed: 29584702
Sci Transl Med. 2019 Jan 2;11(473):
pubmed: 30602536
Cell Rep. 2017 Oct 31;21(5):1399-1410
pubmed: 29091775
JCI Insight. 2017 Aug 3;2(15):
pubmed: 28768910
Int J Mol Sci. 2018 Feb 01;19(2):
pubmed: 29389898
Nat Commun. 2012;3:1227
pubmed: 23187627
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):997-1006
pubmed: 30602457
Neuron. 2016 Jan 6;89(1):37-53
pubmed: 26687838
J Clin Invest. 2014 Sep;124(9):4123-33
pubmed: 25083989
Cell Rep. 2014 Jan 16;6(1):117-29
pubmed: 24373972
J Immunol Res. 2018 Aug 28;2018:1290814
pubmed: 30246031
Immunol Lett. 2008 Aug 15;119(1-2):32-41
pubmed: 18598717
Sci Rep. 2018 May 9;8(1):7352
pubmed: 29743610
Neuropathol Appl Neurobiol. 2018 Feb;44(2):185-206
pubmed: 28767130
Cell Mol Life Sci. 2015 Sep;72(17):3323-42
pubmed: 25985759
Neuro Oncol. 2018 Mar 27;20(4):576-577
pubmed: 29474647
Oncogene. 2016 Dec 15;35(50):6366-6377
pubmed: 27041573
Nat Neurosci. 2005 Jun;8(6):752-8
pubmed: 15895084
Front Cell Neurosci. 2019 Feb 22;13:41
pubmed: 30853898
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Carcinogenesis. 2016 Sep;37(9):839-851
pubmed: 27287871
Neuroscientist. 2015 Jun;21(3):306-21
pubmed: 24871624
Biotechniques. 2005 May;38(5):702, 704, 706
pubmed: 15945368
Acta Neuropathol Commun. 2018 Feb 20;6(1):12
pubmed: 29458417
PLoS One. 2013 Oct 11;8(10):e77571
pubmed: 24147027
Elife. 2017 Dec 18;6:
pubmed: 29251591
J Neuroinflammation. 2020 Apr 16;17(1):120
pubmed: 32299465
Bio Protoc. 2016 Nov 5;6(21):
pubmed: 29104891